Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ORMP

Oramed Pharmaceuticals (ORMP)

Oramed Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ORMP
DateTimeSourceHeadlineSymbolCompany
08/12/202109:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ORMPOramed Pharmaceuticals Inc
08/12/202109:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ORMPOramed Pharmaceuticals Inc
08/12/202108:31Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:ORMPOramed Pharmaceuticals Inc
08/12/202108:31Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:ORMPOramed Pharmaceuticals Inc
29/11/202123:35TipRanksH.C. Wainwright Sticks to Their Buy Rating for Oramed Pharmaceuticals (ORMP)NASDAQ:ORMPOramed Pharmaceuticals Inc
25/11/202109:16Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ORMPOramed Pharmaceuticals Inc
25/11/202100:40PR Newswire (US)Oramed to Join MSCI USA Small Cap IndexNASDAQ:ORMPOramed Pharmaceuticals Inc
24/11/202100:25PR Newswire (US)Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin StudyNASDAQ:ORMPOramed Pharmaceuticals Inc
19/11/202117:30PR Newswire (US)Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin AmericaNASDAQ:ORMPOramed Pharmaceuticals Inc
18/11/202123:40PR Newswire (US)Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin AmericaNASDAQ:ORMPOramed Pharmaceuticals Inc
12/11/202101:25PR Newswire (US)Oramed to Present at H.C. Wainwright 7th Annual Israel ConferenceNASDAQ:ORMPOramed Pharmaceuticals Inc
09/11/202100:10PR Newswire (US)Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq RulesNASDAQ:ORMPOramed Pharmaceuticals Inc
05/11/202108:18Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ORMPOramed Pharmaceuticals Inc
04/11/202102:59PR Newswire (US)Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq RulesNASDAQ:ORMPOramed Pharmaceuticals Inc
29/10/202123:34Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ORMPOramed Pharmaceuticals Inc
29/10/202122:25PR Newswire (US)Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 TrialNASDAQ:ORMPOramed Pharmaceuticals Inc
16/10/202108:16Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:ORMPOramed Pharmaceuticals Inc
23/09/202122:25PR Newswire (US)Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare ConferenceNASDAQ:ORMPOramed Pharmaceuticals Inc
21/09/202106:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ORMPOramed Pharmaceuticals Inc
15/09/202122:10PR Newswire (US)Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% EnrollmentNASDAQ:ORMPOramed Pharmaceuticals Inc
09/09/202122:25PR Newswire (US)Oramed to Present at H.C. Wainwright 23rd Annual Global Investment ConferenceNASDAQ:ORMPOramed Pharmaceuticals Inc
03/09/202106:50Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ORMPOramed Pharmaceuticals Inc
03/09/202106:49Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ORMPOramed Pharmaceuticals Inc
03/09/202106:44Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ORMPOramed Pharmaceuticals Inc
01/09/202122:26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ORMPOramed Pharmaceuticals Inc
01/09/202122:17Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ORMPOramed Pharmaceuticals Inc
01/09/202106:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ORMPOramed Pharmaceuticals Inc
24/08/202122:25PR Newswire (US)Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin TrialsNASDAQ:ORMPOramed Pharmaceuticals Inc
16/08/202122:25PR Newswire (US)Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and MetabolismNASDAQ:ORMPOramed Pharmaceuticals Inc
14/08/202107:06Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(7) (424b7)NASDAQ:ORMPOramed Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ORMP